Actio Biosciences has secured a Series A raise worth $55 million to advance its clinical pipeline in rare diseases, particularly in patients with ion channel TRPV4 mutations.
The San Diego, CA-headquartered company has three assets in its pipeline, led by its unnamed preclinical small molecule program under investigation for Charcot-Marie-Tooth…
Click here to view original post
